SG11201805162VA - Plasmid constructs for heterologous protein expression and methods of use - Google Patents

Plasmid constructs for heterologous protein expression and methods of use

Info

Publication number
SG11201805162VA
SG11201805162VA SG11201805162VA SG11201805162VA SG11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA SG 11201805162V A SG11201805162V A SG 11201805162VA
Authority
SG
Singapore
Prior art keywords
international
rule
pct
applicant
methods
Prior art date
Application number
SG11201805162VA
Inventor
Robert H Pierce
Jean Campbell
David A Canton
Original Assignee
Oncosec Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncosec Medical Inc filed Critical Oncosec Medical Inc
Publication of SG11201805162VA publication Critical patent/SG11201805162VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 1111111101111011101010111110101111101110101101111111111111101111101111011111 International Bureau 0.. .... .. (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/106795 Al 22 June 2017(22.06.2017) WIPO I PCT (51) International Patent Classification: (72) Inventor: PIERCE, Robert H.; 877 Island Avenue, Unit C12N 15/85 (2006.01) A61P 35/00 (2006.01) 1002, San Diego, CA 92101 (US). C12N 15/79 (2006.01) A61K 48/00 (2006.01) C12N 15/63 (2006.01) A61K 39/39 (2006.01) (74) Agent: MOHAN-PETERSON, Sheela; 5820 Nancy C12N 15/09 (2006.01) A61K 39/00 (2006.01) Ridge Drive, San Diego, CA 92121 (US). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/US2016/067388 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (22) International Filing Date: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, 16 December 2016 (16.12.2016) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (26) Publication Language: English MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 62/269,702 18 December 2015 (18.12.2015) US TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, 62/375,245 15 August 2016 (15.08.2016) US ZA, ZM, ZW. (71) Applicant: ONCOSEC MEDICAL INCORPORATED (84) Designated States (unless otherwise indicated, for every [US/US]; 5820 Nancy Ridge Drive, San Diego, CA 92121 kind of regional protection available): ARIPO (BW, GH, (US). GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (72) Inventors; and TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (71) Applicants : CAMPBELL, Jean [US/US]; 839 Northeast TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 92nd St., Seattle, WA 98115 (US). CANTON, David A. DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, [US/US]; 13023 Neddick Ave., Poway, CA 92064 (US). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). [Continued on next page] (54) Title: PLASMID CONSTRUCTS FOR HETEROLOGOUS PROTEIN EXPRESSION AND METHODS OF USE (57) : Provided are plasmid vector constructs encoding multiple immunomod- ulatory proteins where each protein or component thereof can be expressed utiliz- ing appropriate promotors and/or transla- tion modifiers. Additional immunomodu- latory proteins and genetic adjuvants con- taining shared tumor antigens can be added to further therapeutic potential as well as allow tracking of therapeutic treatment. pOMI A, 112 Also provides are methods of expressing the plasmid constructs. 11 ir) CT IN FIG .I 11 Ir ---- 11 ei O WO 2017/106795 Al MIDEDIMOMOIDEIHMEMOMOMENOMMODEVOIS Declarations under Rule 4.17: Published: — as to applicant's entitlement to apply for and be granted — with international search report (Art. 21(3)) a patent (Rule 4.17(0) — before the expiration of the time limit for amending the — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))
SG11201805162VA 2015-12-18 2016-12-16 Plasmid constructs for heterologous protein expression and methods of use SG11201805162VA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269702P 2015-12-18 2015-12-18
US201662375245P 2016-08-15 2016-08-15
PCT/US2016/067388 WO2017106795A1 (en) 2015-12-18 2016-12-16 Plasmid constructs for heterologous protein expression and methods of use

Publications (1)

Publication Number Publication Date
SG11201805162VA true SG11201805162VA (en) 2018-07-30

Family

ID=59057754

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201913163PA SG10201913163PA (en) 2015-12-18 2016-12-16 Plasmid constructs for heterologous protein expression and methods of use
SG11201805162VA SG11201805162VA (en) 2015-12-18 2016-12-16 Plasmid constructs for heterologous protein expression and methods of use

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201913163PA SG10201913163PA (en) 2015-12-18 2016-12-16 Plasmid constructs for heterologous protein expression and methods of use

Country Status (10)

Country Link
US (2) US11713467B2 (en)
EP (1) EP3390643B8 (en)
JP (2) JP7079729B2 (en)
KR (1) KR20190031424A (en)
CN (1) CN109642240A (en)
AU (2) AU2016369608B2 (en)
CA (1) CA3009123A1 (en)
IL (2) IL299646A (en)
SG (2) SG10201913163PA (en)
WO (1) WO2017106795A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6879996B2 (en) 2015-03-26 2021-06-02 オンコセック メディカル インコーポレイテッド How to treat malignant tumors
JP2019519516A (en) 2016-05-18 2019-07-11 モデルナティーエックス， インコーポレイテッド MRNA combination therapy for the treatment of cancer
AU2017331275A1 (en) * 2016-09-23 2019-05-16 Oncosec Medical Incorporated Modulating responses to checkpoint inhibitor therapy
EP3638794A4 (en) * 2017-06-13 2021-03-24 OncoSec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use
GB201710973D0 (en) 2017-07-07 2017-08-23 Avacta Life Sciences Ltd Scaffold proteins
CN107164538B (en) * 2017-07-11 2021-03-02 复旦大学附属华山医院 Internal reference amplification primer composition for detecting CALR gene mutation and amplification system thereof
CN112105723A (en) * 2018-03-08 2020-12-18 鲁比厄斯治疗法股份有限公司 Therapeutic cell systems and methods for treating cancer and infectious diseases
EP3887528A4 (en) * 2018-11-27 2022-12-28 OncoSec Medical Incorporated Plasmid constructs for treating cancer and methods of use
CN113302304A (en) * 2018-12-11 2021-08-24 安克塞克医疗公司 Multi-gene constructs for immunomodulating protein expression and methods of use thereof
KR102524247B1 (en) * 2018-12-21 2023-04-21 가톨릭대학교 산학협력단 p40-EBI3 COMPLEX AND USES THEREOF
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
TW202124722A (en) 2019-09-18 2021-07-01 美商英特佳樂帝克醫療公司 Synthetic dna vectors and methods of use
WO2021074695A1 (en) 2019-10-16 2021-04-22 Avacta Life Sciences Limited PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
CR20220367A (en) * 2020-02-05 2022-08-30 Novartis Ag Cho cell expressing il-15 heterodimers
GB202101299D0 (en) 2020-06-09 2021-03-17 Avacta Life Sciences Ltd Diagnostic polypetides and methods
US12071633B2 (en) 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
CN112126644B (en) * 2020-11-25 2021-03-12 北京立康生命科技有限公司 mRNA (messenger ribonucleic acid) transcribed outside cells under independent cap structure, presenting cell and application
US20240299540A1 (en) 2021-02-05 2024-09-12 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
KR102393402B1 (en) * 2021-03-26 2022-05-04 (주)와이디생명과학 Composition for the preventing or treating cancer comprising an expression vector for dual genes
WO2022234003A1 (en) 2021-05-07 2022-11-10 Avacta Life Sciences Limited Cd33 binding polypeptides with stefin a protein
EP4412711A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Serum half-life extended pd-l1 binding polypeptides
EP4413038A1 (en) 2021-10-07 2024-08-14 Avacta Life Sciences Limited Pd-l1 binding affimers
WO2023153876A1 (en) 2022-02-10 2023-08-17 주식회사 아피셀테라퓨틱스 Stefin a protein variants specifically binding to cd40l, and uses thereof
CN116510022B (en) * 2022-11-23 2023-12-05 武汉滨会生物科技股份有限公司 Anti-tumor composition, recombinant plasmid composition and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL112820A0 (en) * 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
EP0803573A1 (en) * 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
AU4250600A (en) 1999-04-21 2000-11-02 Genzyme Corporation Adenoviral vectors having nucleic acids encoding immunomodulatory molecules
ATE371031T1 (en) * 1999-06-08 2007-09-15 Uab Research Foundation HERPES SIMPLEX VIRUS EXPRESSING THE INTERLEUKIN-12 GENE AND ITS USE IN THE TREATMENT OF CANCER
CN1411512A (en) 1999-10-20 2003-04-16 约翰霍普金斯大学医学院 Chimeric immunogenic compositions and nucleir acids encoding them
US6714816B1 (en) 2000-02-22 2004-03-30 University Of South Florida Electroporation and electrophoresis system and method for achieving molecular penetration into cells in vivo
AU3958101A (en) * 2000-03-15 2001-09-24 Univ Pohang Genes of il-12p40 subunit mutated for improving the activity of il-12 and use thereof for dna vaccine adjuvant
US7245963B2 (en) 2002-03-07 2007-07-17 Advisys, Inc. Electrode assembly for constant-current electroporation and use
US8209006B2 (en) 2002-03-07 2012-06-26 Vgx Pharmaceuticals, Inc. Constant current electroporation device and methods of use
DE10248141B4 (en) * 2002-10-11 2007-04-19 Universitätsklinikum Hamburg-Eppendorf Nucleic acids and their use for gene therapy
US8802643B1 (en) * 2003-05-30 2014-08-12 University Of South Florida Method for the treatment of malignancies
CA2527869A1 (en) 2003-05-30 2004-12-23 University Of South Florida Method for the treatment of malignancies
DE102005055128B4 (en) * 2005-11-15 2015-04-02 Universität Rostock Viral vector, its use for the treatment of hepatocellular carcinoma and pharmaceutical agents comprising the vector
WO2008046251A1 (en) 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Fusion proteins containing n domain of human calreticulin and human papillomavirus type 16 e6 or e7 and uses thereof
US9273300B2 (en) 2007-02-07 2016-03-01 Strike Bio, Inc Methods and compositions for modulating sialic acid production and treating hereditary inclusion body myopathy
KR100911624B1 (en) * 2007-05-14 2009-08-12 연세대학교 산학협력단 Methods for Effectively Coexpressing ????? and ?????
AU2008269032B2 (en) * 2007-06-27 2013-12-05 Novartis Ag Complexes of IL-15 and IL-15Ralpha and uses thereof
RU2573912C2 (en) 2008-10-08 2016-01-27 Интрексон Корпорейшн Constructed cells, expressing multiple immunomodulators, and thereof application
DK2800811T3 (en) 2012-05-25 2017-07-17 Univ Vienna METHODS AND COMPOSITIONS FOR RNA DIRECTIVE TARGET DNA MODIFICATION AND FOR RNA DIRECTIVE MODULATION OF TRANSCRIPTION
US9683237B2 (en) 2014-04-25 2017-06-20 Strike Bio, Inc. Multiple targeted RNAI for the treatment of cancers
PL3277368T3 (en) 2015-03-31 2021-01-25 Oncosec Medical Incorporated Systems for improved tissue-sensing based electroporation
EP3462883B1 (en) 2016-06-07 2023-08-16 The Pacific Heart, Lung,&Blood Institute Compositions and their use in treating cancer
EP3638794A4 (en) 2017-06-13 2021-03-24 OncoSec Medical Incorporated Multigene construct for immune-modulatory protein expression and methods of use

Also Published As

Publication number Publication date
US20210062218A1 (en) 2021-03-04
EP3390643A1 (en) 2018-10-24
IL260039B2 (en) 2023-06-01
IL260039A (en) 2018-07-31
EP3390643B1 (en) 2023-06-28
EP3390643B8 (en) 2023-08-02
US20190153469A1 (en) 2019-05-23
KR20190031424A (en) 2019-03-26
AU2023202722A1 (en) 2023-05-18
JP2018537989A (en) 2018-12-27
CA3009123A1 (en) 2017-06-22
AU2016369608A1 (en) 2018-08-02
SG10201913163PA (en) 2020-03-30
JP2022116129A (en) 2022-08-09
IL299646A (en) 2023-03-01
CN109642240A (en) 2019-04-16
JP7079729B2 (en) 2022-06-02
WO2017106795A1 (en) 2017-06-22
US11713467B2 (en) 2023-08-01
EP3390643A4 (en) 2019-08-28
AU2016369608B2 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
SG11201805162VA (en) Plasmid constructs for heterologous protein expression and methods of use
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201908391XA (en) Methods for modulating an immune response
SG11201909203WA (en) Tissue selective transgene expression
SG11201804373VA (en) Compositions and methods for immunooncology
SG11201809144XA (en) Materials and methods for treatment of hemoglobinopathies
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201811232XA (en) Treatment of amd using aav2 variant with aflibercept
SG11201811603WA (en) Novel adeno-associated virus capsid proteins
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201804647TA (en) Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201807366WA (en) System and method for generating custom shoe insole
SG11201903021WA (en) Anti-human 4-1 bb antibodies and use thereof
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201805320XA (en) Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
SG11201806002SA (en) Methods for extending the replicative capacity of somatic cells during an ex vivo cultivation process
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810627UA (en) Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
SG11201807041PA (en) Improved preparations of adult liver progenitor cells
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression